666 related articles for article (PubMed ID: 27927063)
1. Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis.
Bertrand MJ; Tardif JC
Expert Opin Emerg Drugs; 2017 Mar; 22(1):1-26. PubMed ID: 27927063
[TBL] [Abstract][Full Text] [Related]
2. Emerging anti-inflammatory drugs for atherosclerosis.
Berman JP; Farkouh ME; Rosenson RS
Expert Opin Emerg Drugs; 2013 Jun; 18(2):193-205. PubMed ID: 23675745
[TBL] [Abstract][Full Text] [Related]
3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
4. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk.
Shapiro MD; Fazio S
Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970
[TBL] [Abstract][Full Text] [Related]
5. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
6. The Beneficial Therapy with Colchicine for Atherosclerosis via Anti-inflammation and Decrease in Hypertriglyceridemia.
Spartalis M; Spartalis E; Tzatzaki E; Tsilimigras DI; Moris D; Kontogiannis C; Kaminiotis VV; Paschou SA; Chatzidou S; Siasos G; Voudris V; Iliopoulos DC
Cardiovasc Hematol Agents Med Chem; 2018; 16(2):74-80. PubMed ID: 30526472
[TBL] [Abstract][Full Text] [Related]
7. High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes.
Denegri A; Boriani G
Curr Pharm Des; 2021; 27(2):263-275. PubMed ID: 32679014
[TBL] [Abstract][Full Text] [Related]
8. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies.
Klingenberg R; Hansson GK
Eur Heart J; 2009 Dec; 30(23):2838-44. PubMed ID: 19880848
[TBL] [Abstract][Full Text] [Related]
9. New targets and mechanisms of action for lipid-lowering and anti-inflammatory therapies in atherosclerosis: where does the field stand?
Nicholls SJ; Nelson AJ
Expert Opin Ther Targets; 2024 May; 28(5):375-384. PubMed ID: 38815057
[TBL] [Abstract][Full Text] [Related]
10. New approaches in the diagnosis of atherosclerosis and treatment of cardiovascular disease.
Viljoen A
Recent Pat Cardiovasc Drug Discov; 2008 Jun; 3(2):84-91. PubMed ID: 18537758
[TBL] [Abstract][Full Text] [Related]
11. Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.
Kones R; Rumana U
Drugs; 2015 Jul; 75(11):1201-28. PubMed ID: 26169307
[TBL] [Abstract][Full Text] [Related]
12. Development of anti-atherosclerosis therapy based on the inflammatory and proliferative aspects of the disease.
Maranhão RC; Leite AC
Curr Pharm Des; 2015; 21(9):1196-204. PubMed ID: 25312729
[TBL] [Abstract][Full Text] [Related]
13. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs.
Butters J; Brown A; Griffith L; Kim S; Nicholls SJ
Am J Cardiovasc Drugs; 2017 Dec; 17(6):447-452. PubMed ID: 28432573
[TBL] [Abstract][Full Text] [Related]
15. Potential benefits of eicosapentaenoic acid on atherosclerotic plaques.
Nelson JR; Wani O; May HT; Budoff M
Vascul Pharmacol; 2017 Apr; 91():1-9. PubMed ID: 28263852
[TBL] [Abstract][Full Text] [Related]
16. Clinical value of drugs targeting inflammation for the management of coronary artery disease.
Duchatelle V; Kritikou EA; Tardif JC
Can J Cardiol; 2012; 28(6):678-86. PubMed ID: 22926034
[TBL] [Abstract][Full Text] [Related]
17. [Management of hypercholesterolemia in patients with acute coronary syndrome: current mechanisms and future perspectives].
Lettino M
G Ital Cardiol (Rome); 2016 Apr; 17(4 Suppl 1):31S-7. PubMed ID: 27312021
[TBL] [Abstract][Full Text] [Related]
18. Lipid Lowering Therapy for Atherosclerotic Cardiovascular Disease: It Is Not So Simple.
Vincent J
Clin Pharmacol Ther; 2018 Aug; 104(2):220-224. PubMed ID: 30117592
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies.
Messas N; Dubé MP; Tardif JC
Curr Atheroscler Rep; 2017 Sep; 19(11):43. PubMed ID: 28944433
[TBL] [Abstract][Full Text] [Related]
20. HDL-C: role as a risk modifier.
Barter P
Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
